Greater Cannabis Company (GCAN) Other Non-Current Liabilities (2016 - 2021)
Greater Cannabis Company (GCAN) recorded quarterly Other Non-Current Liabilities of $260905.0 in Q1 2021, up 1395.93% quarter-over-quarter from $17441.0 in Q4 2020, and down 84.69% on a YoY basis from $1.7 million in Q1 2020.
Greater Cannabis Company (GCAN) Other Non-Current Liabilities (2016 - 2021) Analysis & Trends
Greater Cannabis Company's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $260905.0 for Q1 2021.
- In Q1 2021, Other Non-Current Liabilities fell 84.69% year-over-year to $260905.0; the TTM figure through Mar 2021 stood at $260905.0 (down 84.69% YoY), while the FY2020 annual figure was $17441.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities was $260905.0 for Q1 2021 at Greater Cannabis Company, up from $17441.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q1 2020 to a low of $17441.0 in Q4 2019.
- Historically, Other Non-Current Liabilities has averaged $343527.9 across 5 years, with a median of $259142.0 in 2018.
- The sharpest annual moves came in 2020 and 2021: Other Non-Current Liabilities jumped 411.19% in 2020, then sank 84.69% in 2021.
- A 5-year view of Other Non-Current Liabilities shows it stood at $205403.0 in 2017, then sank by 47.21% to $108427.0 in 2018, then plunged by 83.91% to $17441.0 in 2019, then changed by 0.0% to $17441.0 in 2020, then jumped by 1395.93% to $260905.0 in 2021.
- The last three Other Non-Current Liabilities figures came in at $260905.0 (Q1 2021), $17441.0 (Q4 2020), and $325935.0 (Q3 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Greater Cannabis Company | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 260,905.00 |
| Dec 31, 2020 | 17,441.00 |
| Sep 30, 2020 | 325,935.00 |
| Jun 30, 2020 | 539,686.00 |
| Mar 31, 2020 | 1.70 Mn |
| Dec 31, 2019 | 17,441.00 |
| Sep 30, 2019 | 251,367.00 |
| Jun 30, 2019 | 251,367.00 |
| Mar 31, 2019 | 333,432.00 |
| Dec 31, 2018 | 108,427.00 |
| Sep 30, 2018 | 482,667.00 |
| Jun 30, 2018 | 270,502.00 |
| Mar 31, 2018 | 259,142.00 |
| Dec 31, 2017 | 205,403.00 |
| Sep 30, 2017 | 124,731.00 |
| Dec 31, 2016 | 100,000.00 |